everolimus — CareFirst (Caremark)
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent unresectable, advanced, or metastatic breast cancer
Initial criteria
- Requested medication is prescribed in combination with exemestane, fulvestrant, or tamoxifen
Reauthorization criteria
- Continuation may be approved when there is no evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months